Manuel Neves
Overview
Explore the profile of Manuel Neves including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
378
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bergantim R, Geraldes C, Joao C, Lucio P, Neves M, Trigo F, et al.
EJHaem
. 2024 Dec;
5(6):1144-1153.
PMID: 39691257
Objectives: To characterize variations in real-world treatment patterns in multiple myeloma (MM) in Portugal over a 5-year period. Methods: A retrospective cohort multicenter study using secondary data of national hospital...
2.
Geraldes C, Roque A, Sarmento-Ribeiro A, Neves M, Ionita A, Gerivaz R, et al.
Front Oncol
. 2024 Apr;
14:1282300.
PMID: 38585008
Multiple myeloma (MM) is a very heterogeneous disease with multiple symptoms and clinical manifestations. MM affects mainly elderly patients and is difficult to manage in the presence of comorbidities, polypharmacy,...
3.
Joao C, Bergantim R, Santos J, Afonso C, Bernardo P, Coelho H, et al.
Acta Med Port
. 2023 Jul;
36(7-8):517-526.
PMID: 37429590
The treatment of multiple myeloma has profoundly changed with the introduction of several innovative therapies. The optimization of therapeutic sequencing through the combined use of the various drugs developed in...
4.
Constantino C, Leocadio S, Oliveira F, Silva M, Oliveira C, Castanheira J, et al.
J Digit Imaging
. 2023 Apr;
36(4):1864-1876.
PMID: 37059891
The objective is to assess the performance of seven semiautomatic and two fully automatic segmentation methods on [F]FDG PET/CT lymphoma images and evaluate their influence on tumor quantification. All lymphoma...
5.
Ferreira B, Carneiro E, Pestana C, Barahona F, Caetano J, Lopes R, et al.
Front Oncol
. 2022 Jul;
12:860849.
PMID: 35800053
Multiple myeloma (MM) is a hematological malignancy of clonal antibody-secreting plasma cells (PCs). MM diagnosis and risk stratification rely on bone marrow (BM) biopsy, an invasive procedure prone to sample...
6.
Geraldes C, Neves M, Chacim S, Leal da Costa F
Front Oncol
. 2022 Feb;
11:817762.
PMID: 35186719
The recent therapeutic progress in multiple myeloma (MM) has led to the introduction of novel and highly potent drug classes. Daratumumab was the first CD38-targeting antibody showing to be effective...
7.
Neves M, Trigo F, Rui B, Joao C, Lucio P, Mariana N, et al.
Pharmacoeconomics
. 2021 Jan;
39(5):579-587.
PMID: 33517511
Background: Multiple myeloma (MM) is the second most common hematological cancer worldwide and has significant morbidity and mortality and is increasing in incidence. While MM management costs are considerable, specific...
8.
Joao C, Geraldes C, Neves M, Mariz M, Trigo F
J Geriatr Oncol
. 2020 Jul;
11(8):1210-1216.
PMID: 32601004
The management of older patients with Multiple Myeloma (MM) is particularly challenging due to the highly heterogeneous nature of this population, both in terms of physical and cognitive functioning. Older...
9.
Joao C, Bergantim R, Neves M, Chacim S, Afonso C, Barradas J, et al.
Ann Hematol
. 2019 Apr;
98(7):1689-1701.
PMID: 30963200
Patients older than 75 years old with multiple myeloma (MM) have shorter survival and are usually treated differently from what features in clinical trials. In this study, the authors characterized...
10.
Neves M, Azevedo R, Lima L, Oliveira M, Peixoto A, Ferreira D, et al.
N Biotechnol
. 2018 Oct;
49:77-87.
PMID: 30273682
Circulating tumour cells (CTCs) originating from a primary tumour, lymph nodes and distant metastases hold great potential for liquid biopsies by providing a molecular fingerprint for disease dissemination and its...